Drug Approval | June 17, 2025
USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Subscribe To Our Newsletter & Stay Updated
